QCG
MXCT icon

Quadrant Capital Group’s MaxCyte MXCT Stock Holding History

Quadrant Capital Group’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-516
Closed -$2.01K – 2774
2024
Q3 		$2.01K Hold
516
– – ﹤0.01% 2502
2024
Q2 		$2.02K Hold
516
– – ﹤0.01% 2474
2024
Q1 		$2.16K Hold
516
– – ﹤0.01% 2492
2023
Q4 		$2.43K Buy
+516
New +$2.01K ﹤0.01% 2439
2023
Q3 		– Sell
-81
Closed -$372 – 2745
2023
Q2 		$372 Buy
+81
New +$372 ﹤0.01% 2602

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrant Capital Group's MXCT Position: Q4 2024 in Review

Quadrant Capital Group sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 516 shares — an estimated $2.01K sold.

Quadrant Capital Group first reported a position in MXCT in Q2 2023 and held it in 5 quarters. The position peaked at $2.43K in Q4 2023. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

  • Quadrant Capital Group reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 516 MaxCyte shares in Q4 2024, an estimated $2.01K.
  • Quadrant Capital Group first reported a position in MaxCyte in Q2 2023 and held it in 5 quarters.
  • Quadrant Capital Group's MaxCyte position peaked at $2.43K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.